GlycanAge and Circulate Health Validate Glycans as Aging Biomarker

GlycanAge and Circulate Health have published a study confirming that IgG glycans can independently predict all-cause mortality and that biological aging can be reversed through therapeutic plasma exchange, according to a press release.

The research analyzed data from 20,405 individuals across 42 studies conducted between 2008 and 2025. It identified the IgG glycome as a validated and modifiable biomarker of biological aging. The study was led by Professor Gordan Lauc of the University of Zagreb with collaborators from the Buck Institute for Research on Aging, the University of Freiburg, and King's College London.

Three interventions were evaluated for their impact on glycan patterns: therapeutic plasma exchange, hormone replacement therapy, and caloric restriction. Among these, therapeutic plasma exchange produced the largest reduction in glycan age, equivalent to 0.4 years per month. This makes it one of the first demonstrations of the therapy's measurable effect on biological age.

Therapeutic plasma exchange has long been used in autoimmune and neurological treatments. The new data provide structured evidence of its potential in reducing biological age, supporting its use within clinical longevity programs.